Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This early-stage study tested a new drug called TQB3720 in men with advanced prostate cancer that had stopped responding to hormone therapy. The goal was to find a safe dose and see how the drug moves through the body. The study was terminated early, so results are limited.

This study tested two different drug combinations as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. One group received a standard chemo plus bemarituzumab followed by bemarituzumab with anlotinib; the other got che…

This study tested a new drug (TQB3616) combined with either anlotinib or standard chemotherapy in 21 people with advanced lung cancer. The goal was to see if the combination could shrink tumors or slow the disease. The trial was stopped early, so results are limited.

This study tested a new drug called TQB3616 for people with a rare type of cancer called dedifferentiated liposarcoma that could not be removed by surgery. The trial was a phase 2 study comparing the drug to a placebo (a dummy pill) to see if it could slow cancer growth. Only 26 …

This early-stage study tested a new drug (TQB2223) combined with an immunotherapy (penpulimab) in 22 people with advanced liver cancer. The goal was to see if the combination could shrink tumors or slow the disease. The trial was terminated early, so results are limited. Particip…